Literature DB >> 21779446

Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner.

Jingrui Jiang1, James D Griffin.   

Abstract

The FLT3 tyrosine kinase receptor is involved in both hematopoiesis and hematological malignancies. The Wnt/β-catenin pathway has been shown to participate in the self-renewal of hematopoietic stem cells and to cooperate with the mutant FLT3 receptors in leukemic transformation. However, the detailed biological impact of such a constitutively activated Wnt pathway remains to be further explored. Here, the authors report that activating mutations of FLT3 constitutively activate β-catenin by inhibition of GSK-3β in a PI3 kinase pathway-dependent manner. Ectopic expression of a dominant negative form of GSK-3β in FLT3-ITD-expressing cells activated β-catenin and blocked the downregulation of the TCF/β-catenin transcriptional activity induced by inhibition of FLT3 kinase. Furthermore, inhibition of cell proliferation and colony formation induced by such suppression of FLT3 kinase activity could be partially reversed by knockdown of GSK-3β and restored by knockdown of either TCF4 or β-catenin. Moreover, exogenous activation of the Wnt pathway also attenuated such inhibitory effect. These findings indicate that the potencies of the inhibitors of FLT3 kinase activity could be modulated by the activity of the Wnt/β-catenin pathway in the cells harboring FLT3-ITD mutations, and FLT3-ITDs signal through GSK-3β to activate β-catenin that this is likely to directly contribute to the leukemic phenotype.

Entities:  

Keywords:  GSK-3β; Wnt/β-catenin; drug sensitivity; mutant FLT3 receptors

Year:  2010        PMID: 21779446      PMCID: PMC3092187          DOI: 10.1177/1947601910362446

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  46 in total

1.  Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells.

Authors:  F J Staal; B M Burgering; M van de Wetering; H C Clevers
Journal:  Int Immunol       Date:  1999-03       Impact factor: 4.823

Review 2.  WNT signaling in the normal intestine and colorectal cancer.

Authors:  Wim de Lau; Nick Barker; Hans Clevers
Journal:  Front Biosci       Date:  2007-01-01

3.  Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line.

Authors:  Mercy S Chen; Wendy A Woodward; Fariba Behbod; Sirisha Peddibhotla; Maria P Alfaro; Thomas A Buchholz; Jeffrey M Rosen
Journal:  J Cell Sci       Date:  2007-01-16       Impact factor: 5.285

4.  Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

Authors:  Yuki Yuza; Karen A Glatt; Jingrui Jiang; Heidi Greulich; Yuko Minami; Michele S Woo; Takeshi Shimamura; Geoffrey Shapiro; Jeffrey C Lee; Hongbin Ji; Whei Feng; Tzu-Hsiu Chen; Haruhiko Yanagisawa; Kwok-Kin Wong; Matthew Meyerson
Journal:  Cancer Biol Ther       Date:  2007-02-13       Impact factor: 4.742

5.  Dormant Wnt-initiated mammary cancer can participate in reconstituting functional mammary glands.

Authors:  Shelley A Gestl; Travis L Leonard; Jessica L Biddle; Michael T Debies; Edward J Gunther
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

6.  Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.

Authors:  Pascal Furet; Guido Bold; Thomas Meyer; Johannes Roesel; Vito Guagnano
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

7.  A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.

Authors:  F De Toni; C Racaud-Sultan; G Chicanne; V Mansat-De Mas; C Cariven; F Mesange; J-P Salles; C Demur; M Allouche; B Payrastre; S Manenti; L Ysebaert
Journal:  Oncogene       Date:  2006-05-25       Impact factor: 9.867

8.  Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

Authors:  Christian H Brandts; Bülent Sargin; Miriam Rode; Christoph Biermann; Beate Lindtner; Joachim Schwäble; Horst Buerger; Carsten Müller-Tidow; Chunaram Choudhary; Martin McMahon; Wolfgang E Berdel; Hubert Serve
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

9.  Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation.

Authors:  V Stambolic; J R Woodgett
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

10.  Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Authors:  Heidi Greulich; Tzu-Hsiu Chen; Whei Feng; Pasi A Jänne; James V Alvarez; Mauro Zappaterra; Sara E Bulmer; David A Frank; William C Hahn; William R Sellers; Matthew Meyerson
Journal:  PLoS Med       Date:  2005-10-04       Impact factor: 11.069

View more
  8 in total

1.  A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.

Authors:  Panpan Hou; Chao Wu; Yuchen Wang; Rui Qi; Dheeraj Bhavanasi; Zhixiang Zuo; Cedric Dos Santos; Shuliang Chen; Yu Chen; Hong Zheng; Hong Wang; Alexander Perl; Deyin Guo; Jian Huang
Journal:  Cancer Res       Date:  2017-06-16       Impact factor: 12.701

2.  Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Authors:  Xuejie Jiang; Po Yee Mak; Hong Mu; Wenjing Tao; Duncan H Mak; Steven Kornblau; Qi Zhang; Peter Ruvolo; Jared K Burks; Weiguo Zhang; Teresa McQueen; Rongqing Pan; Hongsheng Zhou; Marina Konopleva; Jorge Cortes; Qifa Liu; Michael Andreeff; Bing Z Carter
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 3.  Glycogen synthase kinase-3 and alternative splicing.

Authors:  Xiaolei Liu; Peter S Klein
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-08-17       Impact factor: 9.957

4.  The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.

Authors:  Ulf Schnetzke; Mike Fischer; Anne-Kathrin Kuhn; Bärbel Spies-Weisshart; Elisabeth Zirm; Andreas Hochhaus; Jörg P Müller; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-21       Impact factor: 4.553

5.  Concurrent Evaluation of the Expression and Methylation of secreted frizzled-related protein 2 along with beta-catenin Expression in Patients with non-M3 Acute Myeloid Leukemia.

Authors:  Fatemeh Mirzaeyan; Bahram Chahardouli; Amin Mirzaeian; Nasrin Alizad Ghandforoush; Kamran Alimoghaddam; Shahrbano Rostami
Journal:  Iran J Med Sci       Date:  2021-05

6.  Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway.

Authors:  Tsai-Hsien Hung; Sheng-Chi Hsu; Ching-Yi Cheng; Kong-Bung Choo; Ching-Ping Tseng; Tse-Ching Chen; Ying-Wei Lan; Tsung-Teng Huang; Hsin-Chih Lai; Chuan-Mu Chen; Kowit-Yu Chong
Journal:  Oncotarget       Date:  2014-12-15

7.  Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells.

Authors:  Changbao Chen; Meng Zhao; Aixian Tian; Xiaolin Zhang; Zhi Yao; Xinlong Ma
Journal:  Oncotarget       Date:  2015-07-10

8.  Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.

Authors:  W Fiskus; S Sharma; S Saha; B Shah; S G T Devaraj; B Sun; S Horrigan; C Leveque; Y Zu; S Iyer; K N Bhalla
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.